Hormonal
GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide) significantly improve cardiovascular outcomes and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, though they carry a risk of lean mass loss.
If you have HFpEF and obesity, GLP-1/GIP medications like semaglutide or tirzepatide can significantly improve your heart health, symptoms, and quality of life. To counteract potential muscle loss, you must combine these medications with resistance training and high protein intake. Discuss these options with your cardiologist, as they are increasingly recognized as effective treatments for this specific heart condition.
The STEP-HFpEF trial... demonstrated that once-weekly semaglutide not only led to significant weight reduction but also improved symptoms, physical function, and quality of life (QoL)... Similarly, the SUMMIT trial... found that treatment with tirzepatide resulted in a 38% reduction in the incidence of the composite outcome of CVD death and HFH events compared to placebo.
Why this rating
Based on major randomized controlled trials (STEP, SUMMIT) cited in a narrative review.
Source
The Treatment of Obesity in the Context of the Obesity Paradox in Patients with Heart Failure: A Narrative Review
Pamela L. Alebna et al. · Current Cardiology Reports · 2025
DOI 10.1007/s11886-025-02333-5
More from this paper
- High cardiorespiratory fitness (CRF) mitigates or eliminates the 'obesity paradox' in heart failure, meaning overweight patients with high CRF do not have better survival than normal-weight patients with low CRF.Good
- Anti-obesity medications (AOMs) cause disproportionate loss of lean mass (skeletal muscle), which may worsen frailty and functional capacity in heart failure patients, necessitating concurrent resistance training and protein intake.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →